脾动脉栓塞的临床应用

本文采用经皮导管脾动脉部分栓塞的方法，对门脉高压并脾亢、原发性血小板减少性紫癜、溶血性贫血及外伤性脾破裂进行了栓塞治疗（３１例３３次栓塞），取得了良好效果。并发症为１６．１％，死亡率为３．３％，均较国内（３０％与２０％）国外（２１％与１５．８％）同类水平为低。该方法扩大了栓塞治疗的应用范围，达到了内科久治不愈，病情难以控制，需要外科切脾的目的，既保证了人体解剖的完整性，又保留了脾的免疫功能，具有肯定的临床应用价值。     

部分性脾栓塞术的临床应用：——附37例报告

应用部分脾栓塞术(PSE)治疗难治性原发性血小板减少性紫癜27例,血栓性血小板减少性紫癜1例;难治性再生障碍性贫血2例;Evan's 综合症2例;系统性红斑狼疮合并血小板减少性紫癜2例;继发性脾亢3例.获完全缓解者24例(64.9%);部分缓解者8例(21.6%),总有效率为86.S%.24例获完全缓解者18例追踪1年,6例复发,复发率为33.3%.与25例切脾对照组及文献报道比较,差异无显著性(P>0.05).本文对 PSE 术后外周血小板的变化进行讨论,并与脾切除作了对比。本文还对血小板破坏场、栓塞范围和方法等影响疗效的因素进行了探讨.作者认为 PSE 术可作为脾切除的替代术.     

Minimally Invasive Treatments for Benign Prostatic Hyperplasia: Systematic Review and Network Meta-Analysis

PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications.     

Nontarget Radiopaque Embolic Deposition during Prostatic Artery Embolization

This study evaluated detectable nontarget embolization (NTE) during prostatic artery embolization (PAE) and the safety and efficacy of using radiopaque particles in PAE. Ten patients aged >40 years with prostate glands of >50 mL and refractory lower urinary tract symptoms were analyzed. Unenhanced computed tomography scans at baseline and at 3 months after PAE, using 40–90-μm radiopaque spherical embolic beads, were compared to assess the NTE. Growth models evaluated changes from baseline to 3, 6, and 12 months in International Prostate Symptom Score (IPSS), peak urine flow rate (Qmax), quality of life (QoL), International Index of Erectile Function (IIEF), and postvoid residual (PVR). The IPSS, QoL, and Qmax improved at all time points (P < .05), with no trend in PVR or IIEF. Adverse events that occurred were minor. Radiographic NTE was seen in all patients, correlating at times with postprocedural symptoms (eg, rectal pain). Symptoms were not correlated with the NTE in some patients, whereas other patients remained asymptomatic despite NTE.     

A Pilot First-in-Human Study of Embrace,a Polyethylene Glycol-Based Liquid Embolic Agent,in the Embolization of Malignant and Benign Hypervascular Tumors

PurposeTo investigate the safety and efficacy of an aqueous polyethylene glycol-based liquid embolic agent, Embrace Hydrogel Embolic System (HES), in the treatment of benign and malignant hypervascular tumors.Materials and MethodsA prospective, single-arm, multicenter study included 8 patients, 5 males and 3 females, with a median age of 58.5 years (30–85 years), who underwent embolization in 8 tumors between October 2019 and May 2020. Technical success was defined as successful delivery of HES to the index vessel, with disappearance of >90% of the targeted vascular enhancement or, for portal vein embolization, occlusion of the portal branches to the liver segments for future resection. The volume of HES administered, ease of use (5 point Likert scale), administration time, and adverse events (AEs) were recorded. Evaluation was performed at 7, 30, and 90 days via clinical assessment and blood testing, and follow-up imaging was performed at 30 days.ResultsEight patients were enrolled, and 10 embolizations were performed in 8 lesions. Tumors included hepatocellular carcinoma (n = 4), renal angiomyolipoma (n = 3), and intrahepatic cholangiocarcinoma (n = 1). Technical success was 100%, and the average ease of use was 3.3 ± 1.0 SD. The HES delivery time was 1–28 minutes (median, 16.5 minutes), and the HES volume injected was 0.4–4.0 mL (median, 1.3 mL). All patients reached 30-day follow-up with imaging, and 6 patients reached 90-day follow-up. There were 3 serious AEs in 2 patients that were unrelated to the embolic agent.ConclusionHES resulted in a 100% embolization technical success rate. The product ease of use was acceptable, and no target vessel recanalization was noted on follow-up imaging at 30 days.     

Assessing the Effects of Geniculate Artery Embolization in a Nonsurgical Animal Model of Osteoarthritis

PurposeTo create a nonsurgical animal model of osteoarthritis (OA) to evaluate the effects of embolotherapy during geniculate artery embolization (GAE).Materials and MethodsFluoroscopy-guided injections of 700 mg of sodium monoiodoacetate were performed into the left stifle in 6 rams. Kinematic data were collected before and after induction. At 10 weeks after induction, Subjects 1 and 4–6 underwent magnetic resonance (MR) imaging with dynamic contrast enhancement (DCE) and Subjects 1, 3, and 4–6 underwent angiography with angiographic scoring to identify regions with greatest disease severity for superselective embolization (75–250-μm microspheres). Target vessel size was measured. At 24 weeks after angiography, DCE-MR imaging, angiography, and euthanasia were performed, and bilateral stifles were harvested. Medial/lateral tibial and femoral condylar, patellar, and synovial samples were cut, preserved, decalcified, and scored using the Osteoarthritis Research Society International criteria. The stifle and synovium Whole-Organ Magnetic Resonance Imaging Score and Multicenter Osteoarthritis Study score were determined. The volume transfer constant (K_trans) and extracellular volume fraction (v_e) were calculated from DCE-MR imaging along the lateral synovial regions of interest.ResultsThe mean gross and microscopic pathological scores were elevated at 38 and 61, respectively. Mean synovitis score was elevated at 9.2. Mean pre-embolization and postembolization angiographic scores were 5 and 3.8, respectively. Mean superior, transverse, and inferior geniculate artery diameters were 3.1 mm ± 1.21, 2.0 mm ± 0.50, and 1.6 mm ± 0.41 mm, respectively. Mean pre-embolization and postembolization cartilage and synovitis scores were elevated at 35.13 and 73.3 and 5.5 and 9.2, respectively. The K_trans/v_e values of Subjects 4, 5, and 6 were elevated at 0.049/0.38, 0.074/0.53, and 0.065/0.51, respectively. Altered gait of the hind limb was observed in all subjects after induction, with reduced joint mobility. No skin necrosis or osteonecrosis was observed.ConclusionsA nonsurgical ovine animal knee OA model was created, which allowed the collection of angiographic, histopathological, MR imaging, and kinematic data to study the effects of GAE.     

血流动力学不稳定骨盆骨折的血管造影栓塞诊疗进展

血流动力学不稳定的骨盆骨折病死率超过30％,早期死亡的主要原因是出血及其相关并发症,早期有效控制出血是抢救成功的关键.血管造影栓塞是救治血流动力学不稳定的骨盆骨折的重要技术之一,联合损害控制性复苏、骨盆固定带、外固定支架、腹膜外填塞和复苏性腹主动脉内球囊阻断等技术可进一步提高抢救成功率.本文就血管造影栓塞在血流动力学不...     

单纯铜针留置和铜针留置结合环形缝扎治疗脉管畸形

目的:探讨并总结铜针留置、铜针留置结合环形缝扎治疗脉管畸形的临床应用体会.方法:采用铜针留置、铜针留置结合环形缝扎治疗脉管畸形患者46例,其中静脉畸形43例,动、静脉畸形3例.治疗1～3 次,其中第1次治疗41例,第2次治疗4例,第3次治疗1例,再次治疗至少间隔6个月.观察铜针留置治疗后患者的局部和全身反应,检测其中6例患者铜针留置治疗前及铜针留置治疗5天后血清铜及肝功能变化,数据结果进行统计学分析并对疗效进行评价.结果:本组治疗患者46例,术后随访6～24个月.临床治疗效果:I级(差)3例,占6.5%;II级(中)11例,占23.9%;III级(好)27例,占58.7%;IV级(优)5例,占10.9%.43例(包括中、好和优)脉管畸形患者获得有效治疗(图2～3),总有效率为93.5%.6例留置铜针治疗5天后,血清铜轻度升高,方差分析显示与治疗前相比无显著性差异(P＞0.05);血清丙氨酸氨基转移酶、谷草转氨酶活性轻度升高,秩和检验显示与治疗前相比无显著性差异(P＞0.05).结论:铜针留置简单易行、安全性高,对患者组织形态和功能影响小,是治疗脉管畸形的有效方法之一;铜针留置结合环形缝扎是铜针治疗脉管畸形的改进和发展,可以更有效地治疗脉管畸形,适用于治疗病变范围较大、较深的脉管畸形.     

69例急性下肢缺血的诊治分析

目的探讨急性下肢缺血的治疗方法及预后。方法回顾性分析我科2007年1月～2012年1月治疗69例急性下肢缺血患者的临床资料,其中急性动脉栓塞14例,动脉硬化闭塞基础上继发急性血栓形成50例,血栓闭塞性脉管炎3例,不明原因2例。根据病情采用:动脉切开Fogarty导管取栓8例,人工血管旁路17例;球囊扩张成形/支架置入15例;置管溶栓后进一步行腔内治疗12例;低位静脉动脉化2例;单纯药物治疗9例;I期截肢6例。结果 12例(17.4%)治疗成功,50例(72.5%)治疗好转,1例(1.4%)治疗无效。57例(82.6%)患者获得随访,随访时间3～62(平均26.4)个月,42例症状不同程度改善,7例Ⅱ期截肢,5例死于心、肺疾病。结论急性下肢缺血早期诊断与及时采用合适的治疗方法是治疗成功的关键。     

62例急性肠系膜上动脉栓塞的诊断和治疗

目的探讨急性肠系膜上动脉栓塞的临床表现及早期诊断和治疗方法。方法回顾性分析62例急性肠系膜上动脉栓塞患者的临床资料。结果术前确诊22例(35.5%)。62例患者均行肠系膜上动脉切开取栓,58例患者行坏死肠管切除术,其中35例患者行多次肠管切除术。术后16例患者死亡(25.8%)。术后随访3～24个月。结论肠系膜上动脉栓塞误诊率高,病死率高。对心律失常特别是房颤、心脏瓣膜病及既往有急性动脉栓塞病史患者突发剧烈腹痛,应警惕肠系膜上动脉栓塞可能。肠系膜上动脉切开取栓是治疗急性肠系膜上动脉栓塞缩小肠管切除范围有效方法。